Autre

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

0

0

0 Vues· 09/04/23

OncLive® On Air
0 Les abonnés

Dans

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Montre plus

0 commentaires

Suivant

Lecture automatique

Accueil

Explorez plus

Aider